CASQ1 and catecholaminergic polymorphic ventricular tachycardia: We suggest that the same clinical CPVT phenotype does not imply identical molecular pathogenetic features, depending upon a specific CASQ mutation: key molecules of specific degradative pathways, sHSPs and their phosphorylation status might be interesting topics in understanding cardiac pathophysiology.